Essential Guide to the Psychedelic Renaissance

  • "After a very long and strange trip, psychedelics may finally be back for good."
    • —Rick Doblin, PhD, Founder & Executive Director, MAPS.

Psychedelics and Mental Health

  • "Irene de Caso explains in an understandable and entertaining way the current neuroscientific advances related to psychedelic drugs."
    • —José Carlos Bouso, PhD, Scientific Director, ICEERS.

Your Brain on Psychedelics

  • "To understand the pharmacology of psychedelics is to understand the essence of what makes us human."
  • —José Carlos Bouso, PhD, Scientific Director, ICEERS.

Check out our catalogue

  • Discover how psychedelics promote profoundly revealing mental states capable of restructuring our internal models of the world

Recent news

Check out the latest news on the field of psychedelics.

Read more

EU funds first psychedelics project in Portugal, Netherlands, Czech Republic and Denmark

By Gabriel García on April 5, 2024

The European Union (EU) has taken a historic step by funding for the first time a project that uses psychedelics, such as the well-known “magic mushrooms”, to address the treatment of depression, especially in the field of palliative care and for people with various illnesses. This innovative EU-backed project marks a significant milestone in medical research and treatment of mental and physical health conditions. Psychedelics, compounds that alter consciousness, include lysergic acid diethylamide (LSD), psilocybin (found in magic mushrooms), methylenedioxymethamphetamine (MDMA or ecstasy), dimethyltryptamine (DMT) and ayahuasca, among others.

More information

Read more

Israel joins research on psychedelics

By Gabriel García on March 26, 2024

In a significant step towards researching the therapeutic effects of psychedelics, Israel has joined the international scene through a pioneering collaboration between Optimi Health Corp. and the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). This partnership marks Optimi’s foray into the Israeli psychedelic market and promises to contribute to the advancement of knowledge in the field of mental health and addiction. In this collaboration, Optimi will supply MDMA to the IPR-TLV to support research on the effects of this compound in animal models of alcohol addiction.

More information

Read more

Utah Psychedelics Pilot Programme: A New Frontier in Health Care

By Gabriel García on March 22, 2024

In a bold step towards innovative health options, Utah’s Republican governor, Spencer Cox, has allowed a groundbreaking bill authorising a pilot programme for hospitals to administer psilocybin and MDMA as alternative treatment options to become law despite his reservations. This decision is an important step forward in exploring the therapeutic potential of psychedelics and their role in mental health treatment. Cox, in a letter to legislative leaders, expressed his doubts, but ultimately relented in the face of the “overwhelming support” for the legislation, with both houses unanimously backing the measure.

More information

Read more

The Psychedelic Renaissance: A New Era in Mental Therapy

By Gabriel García on March 15, 2024

The world of mental health is on the verge of a revolution, thanks to a resurgence of interest in psychedelics, known as the Psychedelic Renaissance. This movement is being driven by growing scientific evidence suggesting that substances such as psilocybin, MDMA, DMT, ketamine and LSD have significant therapeutic potential for treating conditions such as depression, anxiety, post-traumatic stress disorder (PTSD) and addiction. The publisher Argonowta has recognised the importance of this phenomenon and has decided to relaunch “The Essential Guide to the Psychedelic Renaissance”, a comprehensive overview of this emerging field.

More information